Encysive Pharmaceuticals Hit With Securities Suit
A Texas-based biopharmaceutical company has been hit with a proposed class action securities suit alleging the company and three executives misled investors about the prospects for the pulmonary arterial hypertension treatment...To view the full article, register now.
Already a subscriber? Click here to view full article